Publication | Closed Access

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

MedicineMelanomaImmunologyPathologyPrimary AnalysisImmune Checkpoint InhibitorFirst-line TreatmentImmunotherapyOncologyRadiation OncologyNovel TherapyMolecular Oncology